[Intravesical instillation of combined adriamycin and verapamil in preventing recurrence of superficial bladder tumor].
Multidrug-resistance of the tumor cells is the main cause for failure of chemotherapy. Such resistance is correlated to P-glycoprotein 170, which can pump the chemotherapeutic agent out of the tumor cells. This action could be reversed by verapamil through competition for closely related binding sites on P-glycoprotein. Twenty-four postoperative cases of superficial bladder tumors were treated by intravesical instillation of combined adriamycin and verapamil, and they were followed up for 17-35 months (average 24.5 months). Two cases (8.7%) had recurrence. NO marked toxicity and side-effects were observed. Verapamil working as a drug-resistance reversing agent might be used in some other tumors not sensitive to chemotherapy.
Liu
N B
NB
China-Japan Friendship Hospital, Beijing.
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D000283:Administration, Intravesical; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D002352:Carrier Proteins / Q000187:drug effects; D004317:Doxorubicin / Q000008:administration & dosage; D004351:Drug Resistance; D005260:Female; D006801:Humans; D008297:Male; D008562:Membrane Glycoproteins / Q000187:drug effects; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000187:drug effects; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000601:surgery; D014700:Verapamil / Q000008:administration & dosage
D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D002352:Carrier Proteins; D008562:Membrane Glycoproteins; D009363:Neoplasm Proteins; D004317:Doxorubicin; D014700:Verapamil